Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 745 clinical trials
Phase IIA Trial of Short-term Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/Gastroesophageal-junction (GEJ) Adenocarcinoma

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of a first-line therapy consisting of induction chemotherapy plus pembrolizumab (12

  • 10 Oct, 2022
  • 1 location
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.

  • 14 Mar, 2022
  • 1 location
Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Single arm multicenter phase II trial evaluating the role of Pembrolizumab in combination to Carboplatin-Paclitaxel chemotherapy in locally advanced cervical cancer patients.

  • 02 Sep, 2021
  • 1 location
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM. This study

  • 18 Apr, 2021
  • 4 locations
Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)

Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis

Accepts healthy volunteers
  • 09 Mar, 2022
  • 3 locations
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG126-pembrolizumab combination regimen in patients with advanced

  • 04 Oct, 2022
  • 1 location
A Pilot Study of Lenvatinib Plus Pembrolizumab in Patients With Advanced Sarcoma

The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be

  • 13 Oct, 2022
  • 7 locations
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

This is an open label investigator initiated Phase II study of single agent pembrolizumab (Keytruda) in metastatic HER2-receptive negative breast cancer patients with germline deletion in the

endocrine therapy
measurable disease
neutrophil count
  • 25 Jan, 2021
  • 2 locations
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers (SMART KEY)

This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx who are candidates for organ preservation.

  • 07 Mar, 2022
  • 1 location
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)

Advanced small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification …

  • 04 Oct, 2022
  • 2 locations